FAZ053

FAZ053 is an investigational monoclonal antibody that targets programmed death ligand 1 (PD-L1). By binding to PD-L1, FAZ053 blocks its interaction with the programmed death 1 (PD-1) receptor and B7.1, thereby inhibiting the PD-L1 immune checkpoint pathway. This action enhances T-cell-mediated anti-tumor immune responses and reverses T-cell inactivation, making cancer cells more susceptible to immune attack. FAZ053 was originally developed by Novartis for use in advanced cancers and has been evaluated in phase 1 clinical trials as both a single agent and in combination with other immunotherapies such as PDR001. In March 2020, Laekna Therapeutics acquired exclusive global rights from Novartis to further develop and commercialize FAZ053.

Other names

anti-pd-l1 monoclonal antibody faz053anti-pd-l-1 monoclonal antibody faz053anti-pd-l 1 monoclonal antibody faz053